Similar articles

• Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.

  Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Tsai HK, et al. J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24. doi: 10.1093/jnci/djm168. Epub 2007 Oct 9. J Natl Cancer Inst. 2007. PMID: 17925537
• Watchful waiting beats androgen deprivation therapy in early prostate cancer.

  Brower V. Brower V. J Natl Cancer Inst. 2008 Nov 5;100(21):1494-6. doi: 10.1093/jnci/djn402. Epub 2008 Oct 28. J Natl Cancer Inst. 2008. PMID: 18957680 No abstract available.
• Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.

  Têtu B. Têtu B. Can J Oncol. 1994 Nov;4 Suppl 1:33-4; discussion 35-6. Can J Oncol. 1994. PMID: 8853487 Clinical Trial. No abstract available.
• Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.

  Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M. Abrahamsson PA, et al. Eur Urol. 2005 Dec;48(6):900-5. doi: 10.1016/j.eururo.2005.09.005. Epub 2005 Oct 11. Eur Urol. 2005. PMID: 16257109 Review.
• Prostate cancer update: 2007.

  Lin AM, Small EJ. Lin AM, et al. Curr Opin Oncol. 2008 May;20(3):294-9. doi: 10.1097/CCO.0b013e3282f8b075. Curr Opin Oncol. 2008. PMID: 18391629 Review.